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Robotic-assisted partial nephrectomy: 
the next gold standard for the treatment 
of intracapsular renal tumors
“Early feasibility studies have demonstrated that robot-assisted 
partial nephrectomy provides equivalent oncological results to 
laparoscopic partial nephrectomy with the further advantage of 
significantly lower intraoperative blood loss, reduced hospital 
stay and warm ischemia time.”
Based on the GLOBOCAN 2008 esti-
mates, published in 2011, over 110,000 
new kidney cancer cases are expected in 
2011, and will account for approximately 
43,000 deaths among men from developed 
countries [1]. Due to increased utiliza-
tion of diagnostic imaging for evaluation 
of patients with abdominal symptoms, 
small renal masses are being diagnosed 
with greater frequency, and over the last 
three decades a stage migration has been 
observed, with an overall decreasing size of 
stage I renal cell carcinoma (RCC) at diag-
nosis [2]. Data from the National Cancer 
Database over the 12-year period between 
1993 and 2004 showed an increase in 
stage I disease and a decrease in stage II, 
III and IV disease (p ≤ 0.001). The size of 
stage I tumors also decreased from a mean 
of 4.1 cm in 1993 to 3.6 cm in 2003 [3]. In 
patients who have incidental detection of 
a renal tumor, there is, on average, a lower 
pathological stage and grade at diagno-
sis, which correlates with a significantly 
increased 5-year cancer-specific survival 
(CSS) as opposed to patients with symp-
tomatic RCC [4]. Indeed, Jemal et al. report 
that the 5-year survival rate of patients 
diagnosed with kidney cancer has pro-
gressively increased from 51% in the mid-
1970s to 69% in the past decade [5], and 
Kane et al. showed a 3.3% increased CSS 
for patients diagnosed in 1998 compared 
with patients diagnosed in 1993 [3]. The 
increased diagnosis of small renal tumors 
has led to a concurrent rise in rates of sur-
gical intervention and to an augmented 
interest in the various techniques of neph-
ron-sparing surgery (NSS) [6]. In this sce-
nario, renal preservation has been progres-
sively prioritized, as approximately 26% 
of patients have impaired renal function 
prior to undergoing either NSS or radical 
nephrectomy (RN) and RN is a recognized 
independent risk factor in the develop-
ment of chronic kidney disease postopera-
tively, cardiovascular events and overall 
mortality [7]. Weight et al. reviewed data 
of 1004 patients with clinical T1b renal 
masses undergoing NSS (n = 524) or RN 
(n = 480). Those patients undergoing RN 
lost significantly more renal function than 
those undergoing NSS. The average excess 
loss of renal function observed with RN 
was associated with a 25% (95% CI: 3–73) 
increased risk of cardiac death and 17% 
(95% CI: 12–27) increased risk of death 
from any cause on multivariate ana lysis [8]. 
Therefore, NSS is an attractive option and 
several studies have shown its oncological 
efficacy compared with RN. A dimensional 
cutoff is still a matter of discussion, but 
according to the European guidelines NSS 
should be performed whenever technically 
feasible in case of intracapsular RCCs up 
to 7 cm in diameter (T1a/b stage) [9]. Data 
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on 3480 patients from the Surveillance and Treatment Update on 
Renal Neoplasms (SATURN) project, promoted by the Italian 
Society of Urology, that collected data from 16 academic centers in 
Italy, displayed no statistical difference in CSS and recurrence free 
survival between patients with clinical stage T1 RCC treated with 
NSS or RN, strongly supporting the use of NSS, consistent with 
the largest monocentric series published in the literature [10–14]. 
Due to its wide use and acceptance, open NSS remains the 
contemporary cornerstone in the management of small renal 
masses, performed either as partial nephrectomy (PN) or tumor 
enucleation (TE), which is a tumorectomy performed by a blunt 
dissection, using the natural cleavage plane between the tumor 
and normal parenchyma, with no ablation of the tumor bed [15–19]. 
Nevertheless, because of its major invasiveness, postoperative 
pain, scarring, longer hospitalization and a slower return to the 
ordinary activities, in the future fewer NSS procedures will be 
conducted using an open fashion. First described by Winfield 
et al. in 1993, laparoscopic NSS (LNSS) duplicates the principles 
of open surgery with several technical variations, as it has been 
standardized to a great extent [20]. Data from the largest compara-
tive study between open PN (OPN) and laparoscopic PN (LPN) 
found it to be a technically feasible, safe and effective option in 
selected patients with RCC who are candidates for a nephron-
sparing procedure [21]. Moreover, in the same series comparing 
LPN to OPN for the treatment of a single renal tumor of 4 cm or 
less, an equivalent oncologic and functional outcomes is reported 
[21]. At 7 years, metastasis-free survival was 93 and 95% (p = 0.7) 
after LPN and OPN, respectively. However, when considering the 
subgroup pT1b/T2 (RCC with a maximum diameter of >4 cm), 
the 5-year metastasis free-survival was 86 and 97% for patients 
treated by LPN and OPN, respectively (p = 0.03), and this differ-
ence was maintained at 7 years of follow-up (82 and 95%, respec-
tively), although it did not reach statistical significance (p = 0.17) 
for the relatively small number of patients in the LPN cohort 
who completed the 7-year follow-up [21]. The authors concluded 
that LPN should only be considered if extended knowledge in 
laparoscopic surgery is available [21,22]. Indeed, LNSS remains a 
challenging procedure, with a steep learning curve, due to the lim-
ited variation of the degree of incidence with the target structures, 
making both the extirpative and reconstructive step often more 
demanding and sometimes approximate in respect to the open 
fashion. Moreover, the laparoscopic approach has been also asso-
ciated with longer warm ischemia time (WIT) when compared 
with OPN [22]. Indeed, in a recent single-center series evaluating 
the short- and long-term renal effect on 362 patients with RCC 
in a solitary kidney, for each 1 min of increasing of WIT there 
was a 5% increased in the risk of postoperative acute renal fail-
ure. Moreover, evaluating warm ischemia in 5-min increments, 
a cutoff point of 25 min provided the best stratification of risk of 
developing acute renal failure or an acute GFR <15 ml/min or a 
new-onset stage IV chronic kidney disease in the postoperative 
period [23]. 
First reported in 2004 by Gettman et al., robot-assisted par-
tial nephrectomy (RAPN) using the da Vinci Surgical System 
(Intuitive Surgical, CA, USA) represents an alternative procedure 
to LNSS and open NSS for the treatment of intracapsular RCCs 
and has steadily gained acceptance between surgeons [24]. Early 
feasibility studies have demonstrated that RAPN provides equiva-
lent oncological results to LPN with the further advantage of 
significantly lower intraoperative blood loss, reduced hospital stay 
and WIT [25]. Recent studies have also shown that RAPN can be 
effectively utilized for the treatment of larger renal tumors that 
are over 4 cm in diameter and in cases of parahilar lesions [26,27]. 
Indeed, the 3D vision associated with the ‘endowrist’ technology 
allows for excellent vision of the operative field and the possibility 
of dissecting the tissue optimally by varying the degree of inci-
dence with the target structures. This is translated into a precise 
and fine renal hilum definition, with the possibility of second-
ary and tertiary arterial branch dissection, in order to perform 
selective or even superselective vascular clamping, providing a 
zero-ischemia partial nephrectomy [28]. After the initial dissection 
directed towards defining the renal hilum and once the tumor 
margins are clearly identified, before clamping, the excision tem-
plate is marked with cautery, a few millimeters away from the 
lesion. More refined instruments and probes are becoming avail-
able to help surgeons in identifying the correct margins, such as 
near-infrared fluorescence of intravenously injected indocyanine 
green and Tile-Pro [29,30]. At this step of the procedure the 3D 
vision and the endowrist also help to decrease the positive surgi-
cal margins as they typically provide optimal dissection angles 
[26,31]. Therefore, a faster and precise extirpative step, without the 
need of repositioning the kidney to achieve an incidental angle, 
that is mandatory during LNSS, allows the surgeon to perform 
a more ergonomic and ‘intuitive’ tumorectomy and to approach 
even more difficult cases, such as large, intraparenchymal or peri-
hilar tumors [26,27]. In these latter cases, when the depth of the 
lesion or the proximity to important vascular structures makes the 
procedure more challenging, the adoption of the TE technique 
can be decisive, as the blunt dissection provides a clear dissec-
tion plane identification, helping the surgeon to discriminate the 
natural cleavage plane existing between the tumor and the renal 
parenchyma. Moreover, TE provides maximal parenchymal pres-
ervation and minimizes incidental calyceal  tearing or vascular 
injuries [32–34]. 
The reconstructive phase of the da Vinci system has the clear 
advantage of being rapid and effective, since the sutures can be 
placed very precisely and with a considerable reduction of time, 
as there is no need to place both the resection bed and the nee-
dle holder in the most convenient position. The result of this 
higher precision and velocity reflects on WIT and on intra- and 
“…the 3D vision associated with the ‘endowrist’ 
technology allows for excellent vision of the 
operative field and the possibility of dissecting the 
tissue optimally by varying the degree of incidence 
with the target structures … [allowing] the surgeon 
to perform a more ergonomic and ‘intuitive’ 
tumorectomy.”
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post-operative complication rates. Indeed, a recent multicenter 
ana lysis that examined surgical outcomes from three experienced 
robotic surgeons reported significantly shorter WIT for RAPN 
when compared with LPN (19.7 vs 28.4 min; p = 0.0001) and 
reported a postoperative complication rate for RAPN of 9.8%, 
comparing favorably with the postoperative complication rate in 
both LPN (18.6%) and OPN (13.7%) [25]. Furthermore, a pro-
spective report on 86 consecutive patients who underwent LPN 
(n = 59) or RAPN (n = 27) showed that an early unclamping tech-
nique was used for 22 patients (82%) in the RAPN cohort and six 
patients (10%) in the LPN cohort (p < 0.001), with a lower WIT 
in the RAPN cohort (mean: 18.5 vs 28.0 min; p < 0.001) [35]. 
Additionally, RAPN has been shown to have a relatively shorter 
learning curve when compared with LPN [25]. The widespread use 
of single-port RAPN will require substantial changes in existing 
robotic instrumentation, since at present it has no proven efficacy 
and is of interest only for anecdotal reports [36]. In conclusion, 
the favorable early-intermediate outcomes of RAPN will extend 
the benefits of the minimally invasive NSS to a wider audience 
of patients and surgeons, making RAPN both the present and 
imminent future of the conservative treatment of kidney cancer. 
Moreover, the da Vinci Surgical System provides the possibility 
of a precise TE, allowing maximal parenchymal preservation and 
minimizing incidental vascular and calyceal tearing.
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